| Literature DB >> 34027422 |
Mona Zamanian-Azodi1, Babak Arjmand2, Mohammadreza Razzaghi3, Mostafa Rezaei Tavirani1, Alireza Ahmadzadeh1, Mohammad Rostaminejad4.
Abstract
INTRODUCTION: Many proteomics-based and bioinformatics-based efforts are made to detect the molecular mechanism of COVID-19 infection. Identification of the main protein targets and pathways of severe cases of COVID-19 infection is the aim of this study.Entities:
Keywords: Bioinformatics; COVID-19; Computational Biology; Network analysis; Proteins
Year: 2021 PMID: 34027422 PMCID: PMC8126352 DOI: 10.22037/aaem.v9i1.1108
Source DB: PubMed Journal: Arch Acad Emerg Med ISSN: 2645-4904
Figure 1The queried 35 differentially expressed proteins (DEPs) are included in a network using STRING database and Cytoscape software
Figure 2The action map for the 35 queried differentially expressed proteins (DEPs) via CluePedia. The blue and red colors of edges refer to binding and inhibition actions
Figure 3Gene ontology results related to the 35 queried differentially expressed proteins (DEPs). The 38 terms are classified in the four groups
List of 38 biological terms related to the queried differentially expressed proteins (DEPs)
|
|
|
|
|
|---|---|---|---|
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | 1 | 4.17 | [ACTB, YWHAE, YWHAZ] |
| Platelet degranulation | 2 | 9.30 | [APOH, CFL1, FGA, FGB, FGG, ORM1, ORM2, PF4, PPBP, TAGLN2, THBS1, TLN1] |
| Platelet activation, signaling and aggregation | 2 | 4.94 | [APOH, CFL1, FGA, FGB, FGG, ORM1, ORM2, PF4, PPBP, TAGLN2, THBS1, TLN1, YWHAZ] |
| Response to elevated platelet cytosolic Ca2+ | 2 | 8.96 | [APOH, CFL1, FGA, FGB, FGG, ORM1, ORM2, PF4, PPBP, TAGLN2, THBS1, TLN1] |
| Hemolytic-uremic syndrome | 3 | 33.33 | [CFHR1, CFHR3, CFI] |
| Atypical hemolytic uremic syndrome | 3 | 33.33 | [CFHR1, CFHR3, CFI] |
| Complement and coagulation cascades | 3 | 7.06 | [CFHR1, CFHR3, CFI, FGA, FGB, FGG] |
| Complement cascade | 3 | 8.62 | [CFHR1, CFHR3, CFI, CFP, CRP] |
| Regulation of Complement cascade | 3 | 8.51 | [CFHR1, CFHR3, CFI, CFP] |
| Hemolytic-uremic syndrome | 4 | 33.33 | [CFHR1, CFHR3, CFI] |
| Hereditary factor I deficiency disease | 4 | 100.00 | [CFI, FGA, FGB, FGG] |
| Dysfibrinogenemia, congenital | 4 | 100.00 | [FGA, FGB, FGG] |
| Afibrinogenemia, congenital | 4 | 100.00 | [FGA, FGB, FGG] |
| Atypical hemolytic uremic syndrome | 4 | 33.33 | [CFHR1, CFHR3, CFI] |
| Complement and coagulation cascades | 4 | 7.06 | [CFHR1, CFHR3, CFI, FGA, FGB, FGG] |
| Platelet activation | 4 | 4.03 | [ACTB, FGA, FGB, FGG, TLN1] |
| Common Pathway of Fibrin Clot Formation | 4 | 18.18 | [FGA, FGB, FGG, PF4] |
| Formation of Fibrin Clot (Clotting Cascade) | 4 | 10.26 | [FGA, FGB, FGG, PF4] |
| Integrin cell surface interactions | 4 | 4.71 | [FGA, FGB, FGG, THBS1] |
| Integrin signaling | 4 | 14.81 | [FGA, FGB, FGG, TLN1] |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | 4 | 26.67 | [FGA, FGB, FGG, TLN1] |
| p130Cas linkage to MAPK signaling for integrins | 4 | 26.67 | [FGA, FGB, FGG, TLN1] |
| MAP2K and MAPK activation | 4 | 12.50 | [ACTB, FGA, FGB, FGG, TLN1] |
| Regulation of TLR by endogenous ligand | 4 | 21.05 | [FGA, FGB, FGG, S100A8] |
| Signaling by moderate kinase activity BRAF mutants | 4 | 10.64 | [ACTB, FGA, FGB, FGG, TLN1] |
| Signaling by high-kinase activity BRAF mutants | 4 | 13.89 | [ACTB, FGA, FGB, FGG, TLN1] |
| Signaling by RAS mutants | 4 | 10.64 | [ACTB, FGA, FGB, FGG, TLN1] |
| Signaling by BRAF and RAF fusions | 4 | 7.46 | [ACTB, FGA, FGB, FGG, TLN1] |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | 4 | 10.64 | [ACTB, FGA, FGB, FGG, TLN1] |
| Oncogenic MAPK signaling | 4 | 6.76 | [ACTB, FGA, FGB, FGG, TLN1] |
| Platelet Aggregation (Plug Formation) | 4 | 10.26 | [FGA, FGB, FGG, TLN1] |
| Signaling downstream of RAS mutants | 4 | 10.64 | [ACTB, FGA, FGB, FGG, TLN1] |
| Regulation of Complement cascade | 4 | 8.51 | [CFHR1, CFHR3, CFI, CFP] |
| Selenium Micronutrient Network | 4 | 5.43 | [CRP, FGA, FGB, FGG, SAA2] |
| Folate Metabolism | 4 | 6.85 | [CRP, FGA, FGB, FGG, SAA2] |
| Blood Clotting Cascade | 4 | 13.04 | [FGA, FGB, FGG] |
| Human Complement System | 4 | 7.07 | [CFI, CFP, CRP, FGA, FGB, FGG, THBS1] |
| Fibrin Complement Receptor 3 Signaling Pathway | 4 | 7.14 | [FGA, FGB, FGG] |
The terms are extracted from Ontology Source; REACTOME_Pathways_08.05.2020, CLINVAR_Human-diseases_08.05.2020, KEGG_08.05.2020, WikiPathways_08.05.2020. Term P Value, term P Value Corrected with Bonferroni step down, group P Value, and term P Value Corrected with Bonferroni step down ≤ 0.01 were considered. GO: gene ontology; N: number of group; AGs: associated genes.
Figure 4Frequency of four classes of biological terms as a pie chart. Different colors indicate designated groups of terms